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CARTILAGE BIOLOGY IN OSTEOARTHRITIS: ACTIVATION OF MATRIX
DEGRADING ENZYMES
C.B. Little1,2, M.T. Jackson1,2. 1Univ. of Sydney, St Leonards, Australia;
2Kolling Inst. of Med. Res., St Leonards, Australia
While osteoarthritis (OA) is a disease involving all joint tissues,
progressive cartilage erosion remains a pathognomonic feature and
a major indicator of the need for replacement surgery. Through
the use of genetically-modiﬁed mice, our understanding of the
molecular mechanisms that drive cartilage erosion in OA has greatly
improved. Factors regulating two particular pathways have emerged as
being critical in modulating OA cartilage pathology: (1) chondrocyte
differentiation/hypertrophy, and (2) proteolysis of key matrix proteins
(aggrecan and collagen) by metalloproteinases. These two pathways
may converge as chondrocyte hypertrophic differentiation is associated
with upregulation of a number of signiﬁcant matrix degrading enzymes
(ADAMTS and MMPs). However, data from MMP-13 KO mice may suggest
it is the MMP activity rather than chondrocyte hypertrophy per se, that
is the critical step in OA-cartilage degradation.
Despite localised pathology we found wide-spread upregulation of
chondrocyte MMP1, 2, 3, 13 and 14 mRNA in OA, suggesting local pro-
enzyme activation regulates focal cartilage breakdown. We identiﬁed the
serine proteinase, activated protein C (APC) but not its zymogen (PC), as
a potential regulator of MMP activation in cartilage. PC and the proteins
necessary for its activation (EPCR, TM) are expressed by chondrocytes,
and PC/APC is increased in areas of MMP activation in OA. In healthy
cartilage, an inﬂammatory stimulus (IL-1, TNF) is required for APC effect.
In contrast, APC alone induces aggrecan and collagen proteolysis by
MMPs in OA human cartilage. The effect of APC was still augmented by
IL-1 stimulation in OA cartilage, even where IL-1 itself had no signiﬁcant
effect on degradation. APC did not regulate expression of MMPs or TIMPs
but increased activation of pro-MMP2, 9 and 13 present in OA human
cartilage.
We found that APC cannot directly activate recombinant pro-MMP2, 9
or 13, and therefore investigated whether it was acting through PARs.
Chondrocyte PAR expression is increased in OA and by inﬂammatory
cytokines, and PARs are implicated in regulating MMP expression and
activation. We found no difference in vitro in basal or IL-1 stimulated
aggrecan or collagen proteolysis, MMP activity or mRNA expression in
PAR-1 or PAR-2 KO compared with wild type (WT) cartilage, suggesting
neither PAR alone is critical for cartilage degradation in mice. We
conﬁrmed this in vivo, observing no change in cartilage erosion compared
to WT in PAR-1 or -2 KO 8 weeks after DMM-induced OA, a time when
MMP-13 activity is critical for cartilage breakdown. In WT cartilage in
the presence of IL-1, APC induced aggrecan and collagen proteolysis,
and pro-MMP2, 9 and 13 activation. There was no diminution in
APC action in PAR-1 or -2 KO cartilage, indicating its effect was
not dependent on either receptor. Surprisingly, APC administration in
WT mice commencing 1 week after DMM surgery and continuing
twice weekly until sacriﬁce (week 8) signiﬁcantly reduced cartilage
degradation. This chondroprotection was not associated with altered
cartilage aggrecan loss nor the appearance of the MMP-cleaved aggrecan
neoepiope DIPEN. Initiating APC treatment 4 weeks after DMM surgery
failed to alter cartilage degradation. These in vivo results implicate the
effects of APC on other tissues in regulating OA cartilage pathology,
and suggest that early intervention, perhaps to modify acute joint
inﬂammation, may be required prevent long-term cartilage degradation
after joint injury.
Local activation of MMPs is a critical step in cartilage degradation in
OA, providing a potential therapeutic target. However, understanding
the interaction between all joint tissues, and the role of inﬂammation in
the initiation and progression of cartilage degradation in post-traumatic
OA requires further investigation.
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DEBATE: IS SUBCHONDRAL BONE OR ARTICULAR CARTILAGE THE
BEST TARGET FOR DMOAD DEVELOPMENT? BONE
D.M. Findlay. Univ. of Adelaide, Adelaide, Australia
Although the major disease of joints, osteoarthritis (OA), is characterised
by progressive degenerative damage to articular cartilage, ultimately it
is a disease of the whole joint. It is clearly important to identify the
cell(s) and tissue(s) that act as initiators of OA because decades of focus
on the articulate cartiage have failed to produce any efﬁcacious drugs
for OA or to prevent or slow the course of this disease. In this debate,
I will assert that it is the subchondral bone, which acts as both the
initiator and driver of OA and present some of the evidence supporting
a role for the subchondral bone in the aetiology and progression of OA.
Firstly, changes in bone shape can result in aberrant loading of joints
or impingement of cartilage, both of which constitute causal factors
for OA. Underlying these gross changes in bone shape are altered bone
micro-structure and changed gene and protein expression, which are
seen in the subchondral bone in OA and which probably occur skeleton
wide in this condition. Secondly, vascular pathology is likely to play a
role in the development of OA, as it does in a number of other skeletal
diseases. I will argue that this has a number of important consequences,
due to reduced subchondral blood ﬂow and ischemia in regions of the
subchondral bone: there is reduced diffusion of nutrients and oxygen
from the bone and marrow compartment to the articular cartilage and
there is death of osteocytes in the subchondral bone. The latter leads to a
cascade of events, which includes the initiation of osteoclastic resorption
of the non-vital bone, which can compromise the bony support for the
overlying cartilage. In addition, increased osteoclast activity in proximity
to the cartilage exposes chondrocytes to catabolic cytokines, such as
IL-1, leading to damage in the overlying articular cartilage. The possible
primary role of the subchondral bone in development of OA refocuses
attention on the bone compartment as a target for DMOADs.
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CHONDROCYTE HOMEOSTASIS
R. Loeser. Wake Forest Universtiy, Winston Salem, NC, USA
Chondrocytes in normal adult articular cartilage do not appear to be
very metabolically active. There is little to no cell proliferation and
matrix turnover appears to be quite low. The half-life of aggrecan has
been estimated to be in the range of 20 years while for type II collagen
it may be close to 100 years. Little is known about the turnover of
other matrix proteins but the expectation is that it would be low as
well. There is evidence that chondrocytes require a certain level of
mechanical stimulation to maintain homeostasis and when joint loading
stops, for example in a paralyzed limb, the cartilage progressively
thins. Because adult articular cartilage lacks a sufﬁcient progenitor
cell population, when chondrocytes die or become dysfunctional they
are not readily replaced with healthy cells. Aging contributes to the
development of osteoarthritis and aging changes affecting homeostasis,
including oxidative stress, are important. There is an age-related cell loss,
particularly in the superﬁcial zone of cartilage. As osteoarthritis develops,
there is evidence for a disruption in normal homeostasis which is made
worse by cell senescence. Besides age, the multiple factors that contribute
to the development of OA, such as joint injury, obesity, joint shape and
alignment, causes changes in the joint tissues that promote chondrocyte
“activation”. This activation is the result of increased activity in a complex
system of cell signaling pathways that results in an increase in synthesis
of cartilage matrix proteins (both normal and abnormal) as well as an
increase in production of inﬂammatory mediators and matrix degrading
enzymes. Matrix degradation generates fragments of matrix proteins
that promote further release of inﬂammatory mediators and matrix
degrading enzymes setting off a vicious cycle resulting in progressive
joint tissue destruction. Further research is needed in order to ﬁnd the
best targets for stopping or reversing this cycle before extensive damage
has occurred.
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PAIN PHYSIOLOGY IN OA
C.I. Svensson. Karolinska Inst.t, Stockholm, Sweden
OA is a common degenerative joint disease, characterized by damage
to articular cartilage, alterations of the underlying subchondral bone,
osteophyte formation and low-grade synovial inﬂammation. The most
prominent feature of OA is joint pain, however, the exact mechanism
of OA-associated pain is unclear and both peripheral and central
mechanisms has been suggested and mixed evidence of inﬂammatory
pain and neuropathic pain noted. Rheumatoid arthritis (RA) is also a
chronic joint disease with progressive cartilage and bone erosion. In
contrast to OA, RA is characterized with prominent joint inﬂammation,
pannus formation and systemic autoantibodies to proteins such as IgG,
type II collagen, citrullinated proteins or glucose-6-phosphate isomerase
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(GPI). Joint pain is frequently reported as the most egregious symptom.
However, though inﬂammation contributes to pain in RA, it may not
be the only factor. For some patients, pain does not improve despite
treatment with anti-inﬂammatory disease-modifying anti-rheumatic
drugs.
Systemic injection of type II collagen and GPI antibodies to mice induces
transient arthritis-like symptoms and joint pathology that resembles
human RA. While these models, called collagen-antibody induced
arthritis (CAIA) and K/BxN serum transfer arthritis (K/BxN) respectively,
are commonly used in the rheumatology ﬁeld, they have prior to our
work not been evaluated as models of arthritis-induced pain. Both
models generate pronounced pain-like behaviors such as mechanical
allodynia and reduced locomotor activity. Strikingly, the pain-like
behaviors occur not only during the inﬂammatory phase but outlast
the inﬂammation by at least four weeks. Of note, cyclooxygenase and
TNF inhibitors only have anti-nociceptive effect during the inﬂammatory
phase, while drugs like gabapentin reduce the hypersensitivity in
both phases, and pentoxifylline only reduces pain behavior during
the late phase, indicating that inﬂammatory and “post-inﬂammatory”
nociception are maintained through different mechanisms in these
models. This, taken together with the observation that ATF-3, a common
marker of nerve injury, is induced in dorsal root ganglia and that spinal
glia are activated in the late phase suggest that joint inﬂammation may
have a nerve damaging effect and that the persistent hypersensitivity
is driven at least in part by spinal sensitization. Interestingly, our
pharmacological and histological ﬁndings from the late phase of the CAIA
and K/BxN models show similarities with published data from animal
models of OA. Hence, our work suggest that a transient episode of joint
inﬂammation and/or joint damage may lead to long-term changes the
sensory system and it is possible that the late phase of the CAIA and
K/BxN models may be useful also for deciphering not only RA, but also
OA pain mechanisms. The aim of this presentation is to give a brief
overview of the physiology of OA pain, introduce the CAIA and K/BxN
models as new models of arthritis-induced pain and discuss similarities
and differences between RA and OA-induced pain from an experimental
point of view.
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GENETICS AND THE FUNCTIONAL ANALYSIS OF OA SUSCEPTIBILITY
LOCI
J. Loughlin. Newcastle Univ., Newcastle upon Tyne, United Kingdom
Genome-wide association scans are beginning to uncover novel
susceptibility loci for OA and these scans, combined with data from
some of the candidate gene based studies, are slowly enlightening our
understanding of the molecular genetic basis of this common arthritis.
Some of the discoveries are to genes whose proteins are known to have
roles in joint formation and maintenance whereas others are to genes
whose encoded proteins have less explicable roles in the articulating
joint. To exploit the genetic data for future use there is a need to
understand the impact OA susceptibility alleles are having on gene and
protein function and to understand how these alleles are themselves
modulated by, amongst other things, epigenetic regulation. This talk will
focus on the genetic and functional analysis of OA susceptibility and
present data on how our understanding of OA susceptibility is enhanced
when we advance from the purely genetic discoveries.
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ADHERENCE TO BEST PRACTICE IN THE CONSERVATIVE
MANAGEMENT OF OSTEOARTHRITIS
N.E. Foster. Keele Univ., Keele, United Kingdom
Peripheral joint osteoarthritis is a major cause of pain and functional
limitations in older adults in the community. Non-pharmacological
interventions play a key role in the holistic management of patients
with osteoarthritis. Advice and education about self-management,
exercise and physical activity, as well as weight loss, for example,
are consistent recommendations for clinical practice in national and
international guidelines [1,2]. These guidelines target patients, the
public and all health professionals involved in the care of this patient
population, including rheumatologists, family doctors, physical therapists
and others. This presentation will summarise best practice for patients
with osteoarthritis with a particular focus on non-pharmacological
interventions and examine the gap between best practice and current
practice, incorporating evidence about this gap from the perspectives of
patients and health care professionals. There are known barriers to the
adoption of best practice and whilst the key barriers will be discussed,
the presentation will focus on ways to improve the uptake of non-
pharmacological interventions in order to optimise patients’ outcomes.
This will include consideration of the potential drivers for change towards
adherence to best practice.
Reference(s)
[1] National Collaborating Centre for Chronic Conditions. Osteoarthritis:
National Clinical Guideline for Care and Management in Adults.
London, England: Royal College of Physicians, 2008.
[2] KM Jordan, NK Arden, M Doherty, B Bannwarth, JWJ Bijlsma, P Dieppe,
K Gunther, H Ha¨uselmann, G Herrero-Beaumont, P Kaklamanis, S
Lohmander, B Leeb, M Lequesne, B Mazieres, E Martin-Mola, K
Pavelka, A Pendleton, L Punzi, U Serni, B Swoboda, G Verbruggen,
I Zimmerman-Gorska, and M Dougados. EULAR Recommendations
2003: an evidence based approach to the management of knee
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INTRA-ARTICULAR INJECTION OF PURIFIED MESENCHYMAL STEM
CELLS FROM C57BL/6 OR MRL/MPJ “SUPERHEALER” MICE PREVENTS
POSTTRAUMATIC ARTHRITIS
B.O. Diekman, C-L. Wu, C.S. Louer, B.D. Furman, J.L. Huebner, V.B. Kraus,
S.A. Olson, F. Guilak. Duke Univ., Durham, NC, USA
Joint injury dramatically enhances the onset of osteoarthritis (OA) and
is responsible for an estimated 12% of OA. In particular, intra-articular
fracture is one of the greatest risk factors for the development of post-
traumatic arthritis (PTA); however, there are no therapeutic options
available that can alter the course of joint disease in this case. Using a
mouse model of PTA, the delivery of mesenchymal stem cells (MSCs)
to the joint was investigated to test the hypothesis that MSCs are
able to prevent PTA by altering the balance of inﬂammation and
regeneration after injury. Additionally, MSCs from c57BL/6 (B6) and
MRL/MpJ (MRL) mouse strains were compared, as MRL “superhealer”
mice have shown exceptional regenerative abilities. A pure population of
MSCs was prospectively isolated from bones using cell surface markers
(CD45-TER119-PDGFRa+Sca-1+). B6 MSCs expanded greater than 100,000
fold in three weeks when cultured at 2% oxygen and displayed greater
adipogenic, osteogenic, and chondrogenic differentiation as compared
to MRL MSCs. Mice receiving only a control saline injection after
fracture demonstrated signiﬁcant increase in cartilage degeneration after
8 weeks, but the delivery of 10,000 B6 or MRL MSCs to the joint was able
to prevent the development of PTA. MSC injection did not reduce the
degree of synovial inﬂammation but did show trends towards increasing
the bone volume during repair. This study provides evidence that adult
stem cell therapy can help prevent the development of PTA after fracture
and has implications for possible clinical interventions after joint injury
before evidence of signiﬁcant OA.
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HIP SHAPE AND OA: PREVENTION AND MANAGEMENT
Y-J. Kim. Children’s Hosp. Boston, Boston, MA, USA
Osteoarthritis of the hip is often due to underlying structural
abnormalities such as acetabular dysplasia, acetabular protrusio,
acetabular retroversion, or pistol grip deformity of the proximal femur.
Acetabular dysplasia is a shallowness of the acetabulum that leads to hip
instability and increased loading at the acetabular rim and osteoarthritis.
Acetabular protrusio, retroversion with or without a pistol grip deformity
of the proximal femur causes mechanical impingement, which may lead
to osteoarthritis. These mechanical causes of osteoarthritis were once
thought to be due to bony remodeling in response to osteoarthritis.
However, new evidence suggests that often these deformities preceed the
development of osteophyte and bony remodeling. Furthermore, some of
these hip deformities are highly prevalent in the general population and
may be an important risk factor for the development of osteoarthritis.
This talk will review the current available evidence that suggests these
structural variations are important as a cause of premature osteoarthritis,
as well as remaining controversies and needed future research. At
